Inhibition of erythropoietin production by cytokines and chemotherapy may contribute to the anemia in malignant diseases.
Jelkmann
W
W
Institute of Physiology, University of Bonn, Germany.
Wolff
M
M
Fandrey
J
J
D000740:Anemia / Q000209:etiology*; D000970:Antineoplastic Agents / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy; D015687:Cell Hypoxia; D016207:Cytokines / Q000009:adverse effects; D004921:Erythropoietin / Q000096:biosynthesis*; D006801:Humans; D007375:Interleukin-1 / Q000009:adverse effects; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects
D000970:Antineoplastic Agents; D016207:Cytokines; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin